News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation

26 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn® AOS for Hard-to-Heal Ulcers

20 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced that the Journal of Infectious Diseases and Treatment has Published Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure

15 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

13 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

07 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100™ (Aviptadil)

07 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders

06 October 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced a Second Favorable Safety Report for ZYESAMI™ (RLF-100TM/aviptadil) in the NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

30 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in the Peer Reviewed Journal of Wound Care, Indicating That Nexodyn® AOS Is a Highly Effective Treatment to Support Wound Healing of Hard-to-Heal Leg Ulcers

30 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)

28 September 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

Monday, September 13, 2021

7:00am EST

Listen to Webcast

Download the Presentation

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

Rx Communication Group
Michael Miller
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: 917.633.6086

Latest News

Corporate News

Archive

Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation

Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn® AOS for Hard-to-Heal Ulcers

Relief Reports that its U.S. Collaboration Partner has Announced that the Journal of Infectious Diseases and Treatment has Published Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure

Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100™ (Aviptadil)

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders

Relief Reports that its U.S. Collaboration Partner has Announced a Second Favorable Safety Report for ZYESAMI™ (RLF-100TM/aviptadil) in the NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in the Peer Reviewed Journal of Wound Care, Indicating That Nexodyn® AOS Is a Highly Effective Treatment to Support Wound Healing of Hard-to-Heal Leg Ulcers

Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)

Events and Presentations

H.C. Wainwright 23rd Annual Global Investment Conference - September 13 - 15, 2021

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events